Spatial Repellents for Malaria Control (AEGIS Uganda)

U

University of Notre Dame

Status

Not yet enrolling

Conditions

Malaria

Treatments

Device: Transfluthrin - delivery by village health teams
Device: Transfluthrin - delivery by paid study personnel
Device: Transfluthrin - delivery by voucher system

Study type

Interventional

Funder types

Other

Identifiers

NCT06122142
23-05-7909

Details and patient eligibility

About

The primary objective of the study is to demonstrate and quantify the effectiveness of a spatial repellent (SR) product, in reducing malaria infection in humans under operational program conditions in a humanitarian assistance context. The design will be a cluster Randomized Control Trial (cRCT) representing an operational research study.

Full description

Spatial repellents (SRs) have been widely used for the prevention of mosquito bites, and preliminary findings suggest efficacy against both malaria and Aedes-borne viruses but their effectiveness in reducing mosquito borne diseases under operational use has never been evaluated. SRs have the potential of being critical tools in the prevention of mosquito borne diseases in contexts where typical vectors control strategies, such as Insecticide-Treated Nets (ITNs) and indoor residual spray (IRS), are inaccessible or underutilized such as among displaced peoples or in emergency relief settings. To address this knowledge gap, the Bidibidi refugee settlement in the Yumbe District of North West Uganda was selected as the study site to estimate the impact of the SR on malaria related outcomes under operational use conditions given ongoing humanitarian relief efforts. Children will be enrolled in 3 separate cohorts to establish effectiveness of SRs in reducing malaria infection in distribution channels. One cohort will estimate the direct effect of the SR distributed through a reference channel (study personnel distribution). The two remaining cohorts will estimate the protection of the SR distributed through a voucher channel and village health team (VHT) channel. Cohorts will be followed twice a month (approximately every 15 days) during the first scheduled household visit in the month, a blood sample will be taken for malaria rapid diagnostic test (RDT) (Monthly Visit #1); and, during the second scheduled household visit, a blood sample will only be taken if the participant has a recent history of fever (Monthly Visit #2). The incidence of malaria in each cohort will be estimated and compared to the reference cohort to determine the benefit of using an SR in an area with high, year-round transmission of malaria.

Enrollment

2,160 estimated patients

Sex

All

Ages

6 to 59 months old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Children ≥ 6 months to ≤ 59 months
  • Children ≥ 6 months to ≤ 59 months with Hb > 7g/dL and no other serious illness
  • Sleeps in cluster (i.e. study area) ≥ 90% of nights during any given month
  • Not participating in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure during the Trial
  • Provision of informed consent form (ICF) signed by the parent(s) or guardian

Exclusion criteria

  • Children < 6 months and > 59 months
  • Children ≥ 6 months to ≤ 59 months with Hb ≤ 7g/dL with signs of other serious illness or Hb ≤ 7 g/dL with signs of clinical decompensation
  • Sleeps in cluster (i.e. study area) < 90% of nights during any given month
  • Participating or planned participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure during the trial
  • No provision of ICF signed by the parent(s) or guardian

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

2,160 participants in 3 patient groups

Study personnel distribution channel
Active Comparator group
Description:
SR product will be delivered by paid study personnel.
Treatment:
Device: Transfluthrin - delivery by paid study personnel
Voucher distribution channel
Experimental group
Description:
Voucher which will be used to redeem for SR product(s) on a monthly basis for each head of household.
Treatment:
Device: Transfluthrin - delivery by voucher system
Village health team distribution channel
Experimental group
Description:
Village health teams will distribute SR products.
Treatment:
Device: Transfluthrin - delivery by village health teams

Trial contacts and locations

2

Loading...

Central trial contact

Nicole L Achee; John P Grieco, Ph.D.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems